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ABSTRACT 
Background: Pentavalent antimony (SbV) has demonstrated therapeutic 
effectiveness against clinical manifestations of leishmaniasis, an infection caused 
by Leishmania,  genus of flagellate protozoa comprising parasites of worldwide 
distribution. Approximately 1.8 million new cases are reported annually. 
Objective: The aim of this study was to assess the pharmacokinetics of the 
investigational generic SbV, Ulamina (pentachloride of antimony + N-methyl- 
glucamine), in healthy adult volunteers. 
Methods: In this study, SbV was administered IM as a single 5-mg/kg dose. 
Blood samples were collected at 0.25, 0.75, 1, 2, 4, 8, 12, and 24 hours after admin- 
istration; urine samples were collected at 6-hour intervals during the 24-hour 
postadministration period. Determination of trivalent antimony, SbV, and total 
antimony concentrations in blood and urine samples was carried out using atomic 
absorption spectrometry. Clinical history was reviewed and the subjects were 
monitored before and after administration of SbV using physical examination, 
weight, and hepatic- and renal-function studies. The pharmacokinetic parameters 
calculated were Cmax, Tmax, absorption constant (Ka), elimination constant (Kd), 
AUC0_24h, AUC0_~, elimination phase (tl/26), volume of distribution (Vd), and uri- 
nary excretion rate. 
Results: Five subjects (3 men, 2 women; mean age, 28 years [range, 18- 
34 years]) were included in the study. One hour after drug administration the 
following values were obtained: Cm~x, 1.1 pg/mL; Tm~x, 1.3 hours; Ka, 1.87 hours; 
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Kd, 0.043 hours; AUC0_24h, 12.26 iJg/mL • h; AUC0_~, 19.84 iJg/mL • h; tl/2[~, 17.45 hours; 
V d, 6.6 L/kg; and urinary excretion rate, 2.8 1Jg/h; these were mean values for the 
entire study group. The single dose was well tolerated by all subjects. 
Conclusions: The investigational generic SbV, Ulamina, was associated with lin- 
ear elimination after IM administration ofa single 5-mg/kg dose. A 2-compartment 
pharmacokinetic model was observed in these volunteers; the mean tl/2[ ~ was 
17.45 hours and the mean V d was 6.6 L/kg. (Curt Ther Res Clin Exp. 2006;67: 
193-203) Copyright © 2006 Excerpta Medica, Inc. 
Key words: pharmacokinetic, antimony, Ulamina, humans, antileishmania 
drugs. 
INTRODUCTION 
Pentavalent antimony (SbV) is a compound erived from the heavy metal anti- 
mony (Sb). In the form of sodium stibogluconate* or meglumine antimoniate, T 
these SbVs have demonstrated effectiveness against the clinical manifesta- 
tions of leishmaniasis, an infection caused by Leishmania. 1-3 This disease is a 
top priority for the tropical disease program of the World Health Organization 
and has a worldwide incidence of -1.8 million new cases annually. 4 
The mechanism of the antileishmanial action of sodium stibogluconate 
remains to be clarified. Exposure to this compound compromises the bioener- 
getics, which diminishes net generation of adenosine triphosphate and guano- 
sine triphosphate of the parasites. 5 The drugs may be administered IM or IV, 
usually as SbV 20 mg/kg • d for 20 to 30 days. 6 The drug causes mild to moder- 
ate adverse events, such as myalgias, arthralgias, abdominal symptoms, 
headache, elevation of aminotransferases and amylases, and electrocardio- 
graphic changes affecting the ST segment and corrected QT interval, all of 
which rarely lead to treatment suspension. Rarely, severe toxicity occurs, such 
as acute renal and hepatic failure, thrombocytopenia, and even sudden death, 
probably due to cardiac rhythm disturbances. 6,7
SbV attains much higher plasma concentrations than trivalent antimony 
(SbIII). Most of a single dose of sodium stibogluconate is excreted in the urine 
within 24 hours. 5 The agent is rapidly absorbed: Tm~x, 2 hours; Cmax, 
9.35 1Jg/mLS; volume of distribution (Vd), -0.22 L/kg; and is eliminated in 2 
phases. The first phase has a short elimination phase (tl/213) of -2 hours, while 
the second phase is much slower (33-76 hours). 5,8 The prolonged terminal tl/2[ 3 
might reflect conversion of SbV to the more toxic and effective SbIII form, which 
accumulates in macrophages and is slowly released from tissues. 5,9 The phar- 
macokinetics of branded drugs, such as sodium stibogluconate and meglu- 
mine antimoniate, are similar with a tl/2[ ~ of 2.17 and 1.92 hours, a Tm~ xof 2 and 
2 hours, and a Cm~ xof 9.35 and 11.23 1Jg/mL, respectively. 8 
*Trademark: Pentostam ® (GlaxoSmithKline, Research Triangle Park, North Carolina). 1° 
tTrademark: Glucantime ® (Rhone-Poulenc, Paris, France, and Aventis, S~o Paulo, Brazil). 11 
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Recent interest in this drug class has focused largely on confirming the efficacy 
of low-cost generic drugs. 3The generic formulations of SbV are valuable alterna- 
tive treatments in countries with a high mortality due to Leishmania parasites. 2,7 
Individual and comparative studies have found that some of the generic formula- 
tions of Sb are as effective as the registered formulations. 12 However, it should be 
pointed out that some generic formulations have been reported to exhibit higher 
cardiotoxicity. 13,14 In Venezuela, the branded meglumine antimoniate is expensive 
and has limited availability due to import costs and a lack of local synthesis. A
generic formulation of SbV, Ulamina, has been synthesized at the Laboratory of 
Chemotherapy and Control in the Jos~ Witremundo Torrealba Center of 
Parasitology Investigations of the University of The Andes (Trujillo, Venezuela). 
Local synthesis of Ulamina has diminished the cost and has been associated with 
clinical response and tolerability similar to that of the branded rug. 15 
We previously conducted a retrospective r view of the medical records of 
416 patients with cutaneous leishmaniasis who were treated exclusively with 
either meglumine antimoniate or Ulamina as the investigational gent o com- 
pare their tolerability. 15A local cutaneous reaction (induration, edema, and ery- 
thema) was reported in the medical records of 22 (13.3%) of the 166 patients 
treated with meglumine antimoniate and in 18 (7.2%) of the 250 patients treated 
with Ulamina. Systemic reactions, such as hypertension, tachycardia, dyspnea, 
hepatitis, fever, headache, dizziness, asthenia, and systemic allergic reaction 
were reported in 5 (3.0%) meglumine antimoniate-treated patients and in 5 
(2.0%) of the patients who received Ulamina. The positive results of the cuta- 
neous hypersensibility test were significantly higher with Ulamina. The Ulamina 
group also showed a significantly lower density (P = 0.024), osmolarity (P = 
0.036), and concentration of chlorates (P = 0.038). 
The objective of the present study was to assess the pharmacokinetics of 
Ulamina after IM administration of a single 5-mg/kg dose to healthy adult human 
volunteers. 
SUBJECTS AND METHODS 
Volunteers and Ethics 
Only healthy adult human volunteers were included in the study. The proce- 
dures and the possible risks associated with the use of Ulamina were explained 
to the volunteers in detail. Written consent to participate in the study, as required 
by the guidelines of the bioethics committee of the Jos~ Witremundo Torrealba 
Center of Parasitology Investigations, was obtained from all participants before 
study initiation. The volunteers were compensated for their participation. 
Volunteers were excluded from the study if they were allergic to Sb, if female 
volunteers were pregnant, if their hemoglobin concentration was <12 mg/L, 
if they had renal dysfunction or hepatic abnormalities (elevated parameters or 
enzymatic modifications), or if they were taking pharmacologic treatment be- 
fore study initiation. 
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Clinical history was reviewed and the following procedures were used for 
assessment of the volunteers before and after administration f Ulamina: phys- 
ical examination, weight, hematology, and hepatic- and renal-function studies 
that included blood glucose, serum creatinine, blood urea nitrogen, serum ala- 
nine aminotransferase, aspartate aminotransferase, total bilirubin, direct biliru- 
bin, alkaline phosphatase, and gamma-glutamyl transpeptidase levels. 
Pharmacologic Material and Doses 
Ulamina (pentachloride of Sb + N-methyl-glucamine) was synthesized at an 
initial dose of 0.3 g/mL of SbV. Mean (SD) results of the Ulamina used in this 
study produced total Sb, 78.25 (23.01) pg/mL; SbV, 77.95 (23.05) pg/mL; SbIII, 
0.20 (0.23) pg/mL; chlorates, 1.61 (0.28) mg/mL; pH, 5.01 (1.57); density, 1.01 
(0.0578) g/mL; and osmolarity, 266 (141.43) mmol/KgH20.15 The drug was admin- 
istered IM as a single 5-mg/kg dose. 
Experimental Design 
An initial blood sample was collected from the volunteers before administra- 
tion of Ulamina; 2-mL blood samples were collected at 0.25, 0.75, 1, 2, 4, 8, 12, 
and 24 hours after treatment. Urine was collected throughout the 24-hour 
postadministration period at intervals of 0 to 6, 6 to 12, 12 to 18, and 18 to 
24 hours. Urine volume was determined for each of those periods, and an aliquot 
of each sample was saved. The blood and urine samples were kept at -6°C, 
lyophilized, and stored for later analysis. 
Analytical Methods 
The concentrations of total Sb and of its species (SbIII and SbV) were deter- 
mined by flow-injection hybrid-generation atomic absorption spectrometry. The 
limits of detection obtained were 2.8 ng/L for SbIII and 3.2 ng/L for SbV. Total Sb 
was calculated as the sum of the concentrations of both species. 16,17 
Pharmacokinetic Analysis 
The following pharmacokinetic parameters were calculated: absorption con- 
stant (Ka); AUC0_24h, which was calculated using the trapezoidal rule for the 
interval of 0 to 24 hours; AUC0_~; tl/2~, determined as ln2/[3, with [3 being calcu- 
lated from the slope of the linear, least-squares regression line; the elimination 
constant (Kel); and the Vd, calculated using the formula dose/AUC × [3.18 Cm~ x
and Tma x were calculated directly from the individual curves. 
The urinary excretion rate of close over time was calculated by dividing the 
total Sb concentration reported (pg) between 6 (interval duration of urine col- 
lected in hours)) 9,2° 
Statistical Analysis 
Plasma concentration versus time curves were determined for each volunteer 
and were analyzed using a noncompartmental model based on the statistical 
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moments theory  18 and using PK Solutions version 2.0 software (Summit Re- 
search Services, Montrose, Colorado). Differences by sex were analyzed statis- 
tically using the Wilcoxon rank sum test, a nonparametr ic  test. P_< 0.05 was con- 
sidered significant. 
RESULTS 
Five healthy adult human volunteers (3 men, 2 women; mean age, 28 years 
[range, 18-34 years])  were included in the study. Table I summarizes the lev- 
els of total Sb, SbIII, and SbV (1Jg/mL) in blood after IM administrat ion of 
Ulamina 5 mg/kg. 
Total Antimony 
The plasma concentrat ion of total Sb and its species as a function of time is 
shown in the figure. The mean plasma Ulamina concentrat ion at 15 minutes 
postadministration was 0.59 1ag/mL, Cm~ xwas 1.1 1ag/mL, and Tm~ xwas 1.3 hours 
(Table II). From that moment on, Sb concentrat ions decreased in 2 phases. The 
first phase of rapid elimination lasted for 4 hours postadministration. The sec- 
ond phase of slower elimination ([3) extended beyond the 24-hour postadminis- 
tration period, with a tl/2[ ~ of 17.45 hours. The difference between the value of 
AUC0_24 h (12.26 1ag/mL • h) and AUC0_ ~ (19.84 1ag/mL • h) was 38.2%, indicating 
that -60% of the drug remained to be eliminated. 
Other pharmacokinetic parameters of total Sb and the mean values obtained 
from the analysis of the curves of each volunteer are shown in Table If. The Ka 
was 1.88 hours, the Kel was 0.043 hour, and V d was 6.66 L/kg. 
Pentavalent Antimony 
The profile of SbV was similar to that of total Sb. The phases of rapid elimina- 
tion and slow elimination were observed: Kel was 0.056 hour, V d was 8.55 L/kg, 
and AUC0_24 h was 12.76 pg/mL • h (Table llI). 
Trivalent Antimony 
The profile of SbIII had a significantly lower Kel (0.014 hour, P = 0.043) com- 
pared with SbV, was associated with a significantly greater V d (29.3 L/kg, P = 
0.043) than SbV, and had an AUC0_24 h of 0.18 pg/mL • h. 
A decrease in SbV concentrat ion was observed 2 hours after administration, 
with systemic conversion in SbIII of 23.3%. The mean urinary excretion rate of 
Ulamina was determined to be 2.8 pg/h. 
No significant difference was found in pharmacokinetic parameters between 
sexes. 
The findings with regard to the demographic  data (ie, age, sex, weight) and 
safety monitor ing (renal and hepatic function and hematology)  before and 
24 hours after administration of Ulamina for the 5 volunteers are shown in 
Table IV. No adverse events were reported after this single dose. 
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Figure. Mean concentration of total antimony (Sb) and its species (pentavalent Sb 
[SbV] and trivalent Sb [Shill]) in healthy adult volunteers (N = 5) who 
received a single 5-mg/kg IM dose of Ulamina. 
DISCUSSION 
Ulamina is an experimental SbV for the treatment of leishmaniasis in Venezuela. 15 
A Cm~ of 1.12 pg/mL, with a Tm~ of 1 hour and a Ka of 1.87 hours, suggests a 
fast and complete absorpt ion for Ulamina. 
In the present study, metabol ism of the drug resulted in a decrease in SbV 
concentrat ion 2 hours after administration, with systemic onvers ion of 23.3%. 
For the next 12 hours this percentage was maintained. The drug was distr ibuted 
at the t issue level, at a rate of V d 6.66 L/kg. The concentrat ion of SbIII depended 
on the reduction process of SbV convert ing into SbIII. 21 As reported with the 
Table II. Pharmacokinetic parameters of total antimony after IM administration of 
Ulamina 5-mg/kg to healthy adult human subjects. 
Volunteer 
Parameters 1 2 3 4 5 Mean (SD) 
C . . . .  pg/mL 1.0 1.1 1.1 1.3 1.1 1.1 (0.070) 
Tmax, h 1.0 0.8 0.8 3.0 1.1 1.3 (0.501) 
Ka, h 2.70 0.27 2.90 1.35 2.1 7 1.88 (1.08) 
AUC0_24h, [Jg/mL • h 13.1 15.5 8.5 14.9 9.3 12.3 (2.866) 
AUC0_~, [Jg/mL • h 29.0 21.8 14.2 21.9 12.3 19.8 (6.72) 
tl/213, h 8.07 12.58 19.12 14.41 13.11 13.46 (6.46) 
Kel , h 0.024 0.055 0.036 0.048 0.052 0.043 (0.012) 
Va, L/kg 6.98 4.16 9.74 4.74 7.67 6.66 (2.26) 
Ka = absorption constant; t1/213 = elimination phase; Kel = elimination constant; V d = volume of distribution. 
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Table III. E l iminat ion level observat ions for  t r iva lent  ant imony  
(Shil l) ,  pentava lent  Sb (SbV), and tota l  Sb in 5 hea l thy  
adu l t  subjects af ter  IM admin is t ra t ion  of U lamina 
5-mg/kg.  
Sblll SbV Total Sb 
Kel , h 0.014* 0.056 0.043 
Vd, L/kg 29.30 t 8.55 6.66 
AUC0_24h, [Jg/mL • h 0.18 1 2.76 1 2.26 
Kel = elimination constant; V d = volume of distribution. 
*P = 0.043 versus SbV. 
tp = 0.043 versus SbV. 
sodium stibogluconate, 5 Ulamina was associated with -20% of the plasmatic Sb 
remaining in the trivalent form. A positive balance of SbIII resulted from the con- 
version of SbV to SbIII, possibly at the hepatic or systemic level. 5,8 
The pharmacokinetics of Ulamina in these subjects was consistent with a 
2-compartment model of elimination, with a V d of total Sb (6.6 L/kg), which was 
larger than descr ibed for other formulations. The V d for sodium stibogluco- 
nate was found to be -0.22 L/kg in other studies. 5,8 Ulamina was completely 
absorbed, and it was thought hat the drug was retained in the tissues and elim- 
inated slowly. Because the difference between Cm~ x (1.12 pg/mL) and minimum 
concentrat ion at 24 hours (0.28 pg/mL) was small and the difference between 
AUC0~ and AUC0_24 h was  38.2%, this suggested that a large percentage of the 
drug had not been eliminated after 24 hours. The capacity of the macrophages 
to accumulate Sb has been descr ibed to be at least 3 days. 8,9 This might explain, 
in part, the low plasma Ulamina concentrat ions in humans. Binding of the drug 
to tissues and to intracellular proteins might also be involved. 5 SbIII had a 
greater V d than SbV in this study, possibly owing to its greater ability to react 
electrochemically. 22 These pharmacokinetic characterist ics are shared with 
arsenic, whose trivalent species have been descr ibed as interacting with the 
thiol groups of proteins21; a mechanism that contr ibutes to increased tissue 
retention. 22 Indeed, this has been suggested to be one of the mechanisms 
accounting for the leishmanicidal effects of Sb. 9 
Ulamina followed a kinetic of linear elimination after administration i a single 
5-mg/kg dose. The last phase of elimination appeared ependent on the release 
of the drug from the tissues. The measured tl/2[ ~ of Ulamina was 17.45 hours, 
whereas tl/2[ ~ for branded formulations has been reported to be 33 to 76 hours. 5 
The principal route of elimination of SbV was renal. 5,8,23,24 Urinary excretion of 
Ulamina occurred at a mean rate of 2.8 pg/h, which was probably dependent on 
low plasma concentrations. 
The present study was limited by its small sample size. In addition, these 
results might not be generalizable to all patients with leishmaniasis or renal dis- 
ease, in whom it is necessary  to characterize the pharmacokinetics of Ulamina. 
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CONCLUSIONS 
Ulamina followed linear elimination kinetics after its administration i a single 
5-mg/kg dose. In these 5 volunteers, the drug followed a 2-compartment phar- 
macokinetic model, with a tl/2[ 3 of 17.45 hours and V d of 6.6 L/kg. These proper- 
ties suggested that Sb might accumulate after multiple administrations. 
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